ライフサイエンスコーパス: zeaxanthin

1 ; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin).

2 ne, beta-carotene, lycopene, and lutein plus zeaxanthin.

3 es, including the unique macula pigment meso-zeaxanthin.

4 on of all-E-lutein and puffing also of all-E-zeaxanthin.

5 otene (20%), with minor levels of lutein and zeaxanthin.

6 ay can provide a high enough level (2 mg) of zeaxanthin.

7 e was rich in antheraxanthin, capsanthin and zeaxanthin.

8 est degradation rates followed by lutein and zeaxanthin.

9 well as the tightly regulated production of zeaxanthin.

10 to be partially phosphorylated and contained zeaxanthin.

11 r adjusting for dietary intake of lutein and zeaxanthin.

12 pha-carotene, beta-cryptoxanthin, and lutein/zeaxanthin.

13 ellow, blue-absorbing carotenoids lutein and zeaxanthin.

14 aggregate of the carotenoid all-trans 3R,3'R-zeaxanthin.

15 ls showing continuous exposure to lutein and zeaxanthin.

16 is affected by both DeltapH and the level of zeaxanthin.

17 e-epoxidation of LHCII-bound violaxanthin to zeaxanthin.

18 otene (0.84; 95% CI: 0.77, 0.93), and lutein/zeaxanthin (0.87; 95% CI: 0.79, 0.95).

19 tene, 0.28; beta-cryptoxanthin, 0.35; lutein/zeaxanthin, 0.28; lycopene, 0.15; folate, 0.26; alpha-to

20 arotene, 0.53; beta-carotene, 0.39; lutein + zeaxanthin, 0.46; lycopene, 0.32; and alpha-tocopherol,

21 [98.7% CI, 0.76-1.07]; P = .12 for lutein + zeaxanthin; 0.97 [98.7% CI, 0.82-1.16]; P = .70 for DHA

22 otene (1.04; 95% CI: 0.98, 1.10), and lutein/zeaxanthin (1.00; 95% CI: 0.93, 1.07).

23 1 of the following 4 groups: placebo; lutein/zeaxanthin, 10 mg/2 mg; omega-3 long-chain polyunsaturat

24 capsule containing 10 mg of lutein, 1 mg of zeaxanthin, 100 mg of docosahexaenoic acid, and 30 mg of

25 e randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated

26 acids (LCPUFAs) (1 g) and/or lutein (10 mg)/zeaxanthin (2 mg) vs placebo were tested in a factorial

27 were randomized to receive lutein (10 mg) + zeaxanthin (2 mg), DHA (350 mg) + EPA (650 mg), lutein +

28 .86+/-1.76 mug/g) while mais has the highest zeaxanthin (269.1+/-11.8 mug/g).

29 % (468 eyes [399 participants]) for lutein + zeaxanthin, 31% (507 eyes [416 participants]) for DHA +

30 id contents (beta carotene, 14.25 mug/100 g; zeaxanthin, 35.21 mug/100 g; lutein 174.59 mug/100 g) as

31 ing of phycobilisomes rods and regulation of zeaxanthin abundance.

32 Studies in BCO2-knockout mice revealed that zeaxanthin accumulates in the inner mitochondrial membra

33 oducts and/or state 1-state 2 transitions or zeaxanthin accumulation, namely, npq4, stt7, stt7 npq4,

34 , which is necessary for the accumulation of zeaxanthin, affects the excited-state chlorophyll relaxa

35 idual carotenoid contents, including lutein, zeaxanthin , alpha-carotene, beta-carotene, and lycopene

36 Sastra showed the highest content of zeaxanthin among the fruit investigated.

37 oxide, together with (all-E)-lutein, (all-E)-zeaxanthin and (all-E)-beta-carotene were found at high

38 the relations between intakes of lutein and zeaxanthin and age-related macular degeneration (AMD) ha

39 as characterized by high levels of all-trans-zeaxanthin and all-trans-beta-carotene (755 and 332mug/g

40 or xanthophylls (all-trans-lutein, all-trans-zeaxanthin and all-trans-beta-cryptoxanthin).

41 immon powder for all-trans-lutein, all-trans-zeaxanthin and all-trans-beta-cryptoxanthin, respectivel

42 est, including the structural isomers lutein/zeaxanthin and alpha-/beta-carotene.

43 as the direct comparison between lutein plus zeaxanthin and beta-carotene, were assessed for genotype

44 plasma xanthophyll concentrations (lutein + zeaxanthin and beta-cryptoxanthin) and hydrocarbon carot

45 n were the free hydroxy xanthophylls lutein, zeaxanthin and beta-cryptoxanthin.

46 is-violaxanthin, lutein, beta-cryptoxanthin, zeaxanthin and cis-antheraxanthin) were investigated at

47 Pistachios were rich in lutein/zeaxanthin and contained highest beta-carotene levels am

48 [98.7% CI, 0.75-1.06]; P = .10 for lutein + zeaxanthin and DHA + EPA).

49 2 mg), DHA (350 mg) + EPA (650 mg), lutein + zeaxanthin and DHA + EPA, or placebo.

50 % (472 eyes [387 participants]) for lutein + zeaxanthin and DHA + EPA.

51 hin monomeric LHC proteins depending on both zeaxanthin and lutein and on the formation of a radical

52 mical quenching, despite the absence of both zeaxanthin and lutein and show that tobacco can regulate

53 The highest content of zeaxanthin and lutein was found in 'Verde di Macerata' a

54 arotene and the non-provitamin A carotenoids zeaxanthin and lutein, and is inactive with all-trans-ly

55 in the npq1 lor1 double mutant, which lacks zeaxanthin and lutein.

56 ntensity on the presence and accumulation of zeaxanthin and lutein.

57 Year 0 lutein/zeaxanthin and lycopene were not associated with maximum

58 n mice and primates of a binding protein for zeaxanthin and meso-zeaxanthin, the pi isoform of glutat

59 e protective carotenoid pigments, especially zeaxanthin and myxoxanthophyll, were up-regulated in the

60 nge peppers were the best sources of lutein, zeaxanthin and neoxanthin.

61 tial interactions between LCPUFAs and lutein/zeaxanthin and none were found to be significant.

62 eration of a strain constitutively producing zeaxanthin and showing improved photosynthetic productiv

63 Kernels from the tip-end had highest zeaxanthin and TC in the zeaxanthin biofortified sweet-c

64 ends on the nutritional uptake of lutein and zeaxanthin and that it is inversely associated with the

65 healthy diet in regard to B-vitamins, lutein/zeaxanthin and tocopherols.

66 n, while an opposite effect was observed for zeaxanthin and violaxanthin.

67 ding protein of photosystem II) or pigments (zeaxanthin and/or lutein) required for photoprotective t

68 ndomized controlled clinical trial of lutein/zeaxanthin and/or omega-3 fatty acids, the Age-Related E

69 luate the efficacy and safety of lutein plus zeaxanthin and/or omega-3 long-chain polyunsaturated aci

70 and tocotrienols), xanthophylls (lutein and zeaxanthin) and flavonoids (3-deoxyanthocyanidins-3-DXAs

71 -based macular xanthophylls (MXs; lutein and zeaxanthin) and the lutein metabolite meso-zeaxanthin ar

72 We did not detect any activity with lutein, zeaxanthin, and 9-cis-beta-carotene.

73 content on a chlorophyll basis, particularly zeaxanthin, and a major down-regulation of light absorpt

74 s, for alpha- and beta-carotene, lutein plus zeaxanthin, and alpha-tocopherol.

75 enotypes was lutein, followed by its esters, zeaxanthin, and beta-carotene, while antheraxanthin and

76 the contents of free amino acid, lutein and zeaxanthin, and increased the MDA content in eggs.

77 nthin, alpha-carotene, beta-carotene, lutein/zeaxanthin, and lycopene) and the evolution of lung func

78 ng affinities between human BCO2 and lutein, zeaxanthin, and meso-zeaxanthin are 10- to 40-fold weake

79 The prevalence of lutein, zeaxanthin, and meso-zeaxanthin in supplements is increa

80 nce on the putative role of the MXs (lutein, zeaxanthin, and meso-zeaxanthin) in AMD and report findi

81 ounts of the xanthophyll carotenoids lutein, zeaxanthin, and meso-zeaxanthin, but the underlying bioc

82 nt containing a fixed combination of lutein, zeaxanthin, and omega-3 LC-PUFAs during 12 months signif

83 Nutritional uptake of lutein, zeaxanthin, and omega-3 polyunsaturated fatty acids may

84 containing 20 mg/day of lutein, 4 mg/day of zeaxanthin, and other antioxidants (vitamin C, vitamin E

85 LHCs), the de-epoxidation of violaxanthin to zeaxanthin, and the photosystem II subunit S (PsbS) work

86 convolution of the relative contributions of zeaxanthin- and lutein-dependent NPQ.

87 Mathematical models of the response of zeaxanthin- and lutein-dependent reversible NPQ were con

88 lacks VDE and cannot convert violaxanthin to zeaxanthin; and npq1 npq4, which lacks both VDE and PsbS

89 total content of carotenoids (sum of lutein, zeaxanthin, antheraxanthin, alpha- and beta-carotene, an

90 Five carotenoids, namely lutein, zeaxanthin, antheraxanthin, alpha- and beta-carotene, we

91 human BCO2 and lutein, zeaxanthin, and meso-zeaxanthin are 10- to 40-fold weaker than those for mous

92 rs and former smokers and because lutein and zeaxanthin are important components in the retina.

93 tional changes under the presence of DeltapH/zeaxanthin are related to the PsbS role in the current n

94 d zeaxanthin) and the lutein metabolite meso-zeaxanthin are the major constituents of macular pigment

95 Among the carotenoids, lutein and zeaxanthin are the only two that cross the blood-retina

96 Lutein and zeaxanthin are xanthophyll carotenoids that are highly c

97 Shortage of the dietary carotenoids lutein, zeaxanthin as well as fish consumption are reported AMD

98 Adjusting for dietary lutein and zeaxanthin attenuated, and therefore partially explained

99 Thiamine, riboflavin, pyridoxine, lutein, zeaxanthin, beta-carotene and alpha-/gamma-tocopherol we

100 Levels of lutein, zeaxanthin, beta-cryptoxanthin and beta-carotene in hexa

101 surface responses were generated for lutein, zeaxanthin, beta-cryptoxanthin and beta-carotene in kaki

102 ds in humans (phytoene, phytofluene, lutein, zeaxanthin, beta-cryptoxanthin, alpha-carotene, beta-car

103 ng time on the bioactive components (lutein, zeaxanthin, beta-cryptoxanthin, phytate, tannin and vita

104 a-carotene, beta-carotene, lycopene, lutein, zeaxanthin, beta-cryptoxanthin, retinol, alpha-tocophero

105 eshly harvested orange hybrid maize; lutein, zeaxanthin, beta-cryptoxanthin, tannin and vitamin C inc

106 ncludes variants in or near genes related to zeaxanthin binding in the macula (GSTP1), carotenoid cle

107 ric antenna complexes of Photosystem II upon zeaxanthin binding; however, the amplitude of carotenoid

108 gy were evaluated in all yogurt samples, and zeaxanthin bioaccessibility after in vitro digestion was

109 tip-end had highest zeaxanthin and TC in the zeaxanthin biofortified sweet-corn, and highest lutein a

110 C) and quality parameters was evaluated in a zeaxanthin-biofortified and a commercial yellow sweet-co

111 n resulted in significant inhibition of meso-zeaxanthin biosynthesis during chicken eye development.

112 se of the system, we assembled the five-gene zeaxanthin biosynthetic pathway in a single step and sho

113 vitamin C, beta-cryptoxanthin, and lutein + zeaxanthin but lower folate and vitamin D concentrations

114 yll carotenoids lutein, zeaxanthin, and meso-zeaxanthin, but the underlying biochemical mechanisms fo

115 itro oxidation of beta-carotene, lutein, and zeaxanthin by (1)O(2) generated various aldehydes and en

116 ble for the transformation of lutein to meso-zeaxanthin by a double-bond shift mechanism, but its ide

117 into consideration, the idea that lutein and zeaxanthin can influence cognitive function in older adu

118 ation of individual carotenoids such lutein, zeaxanthin, canthaxanthin, ss-carotene and beta-apocarot

119 st that increased dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsatur

120 In contrast, zeaxanthin cleavage dioxygenase (ZCD), an enzyme previou

121 monstrated that only mouse BCO2 is an active zeaxanthin cleavage enzyme.

122 as significantly related to serum lutein and zeaxanthin combined (r = 0.31, P = 0.002), GD (r = 0.24,

123 However, if a threshold zeaxanthin concentration is to be achieved, the position

124 ation-based study in centenarians found that zeaxanthin concentrations in brain tissue were significa

125 a relation between cognition and lutein and zeaxanthin concentrations in the brain tissue of deceden

126 change in provitamin A carotenoid and lutein/zeaxanthin concentrations was associated with a slower d

127 Differences in lutein and zeaxanthin concentrations were small.

128 Arabidopsis thaliana mutant that accumulates zeaxanthin constitutively, have reported that this xanth

129 nt with the high rate of habitual lutein and zeaxanthin consumption in Utah AREDS2 subjects prior to

130 While zeaxanthin content was highly influenced by the ACC (up

131 This type of quenching, together with high zeaxanthin content, appears to underlie photoprotection

132 Lutein and zeaxanthin contents were lower in non-corn cereal endosp

133 e of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute

134 REDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than beta carotene

135 REDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than beta-carotene

136 cherichia coli strains engineered to produce zeaxanthin demonstrated that only mouse BCO2 is an activ

137 photomixotrophically at moderate light, the zeaxanthin-dependent component of NPQ emerged upon stron

138 ential spectroscopy in vivo, we identified a zeaxanthin-dependent optical signal characterized by a r

139 enetically dissected different components of zeaxanthin-dependent photoprotection.

140 relative to D3, combined with an increase in zeaxanthin-dependent quenching (qZ) relative to D4.

141 component of quenching was less dependent on zeaxanthin, despite the near-complete violaxanthin to ze

142 Addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation

143 e main fraction among berry varieties having zeaxanthin di-palmitate as major compound, while leaves

144 ed, including beta-carotene and 10 different zeaxanthin-di-esters.

145 as not modified after 6 months of lutein and zeaxanthin dietary supplementation despite plasma levels

146 ) for those randomized to not receive lutein/zeaxanthin (difference in yearly change, 0.03 [99% CI, -

147 antioxidant activity and contents of rutin, zeaxanthin dipalmitate and 2-O-beta-d-glucopyranosyl-l-a

148 ied by an accumulation of up to 36mg/100g FW zeaxanthin dipalmitate and further minor xanthophyll est

149 In the case of zeaxanthin dipalmitate the retention level was around 40

150 rotenoid found in wheat and tritordeum while zeaxanthin dominated in barley.

151 1 (high pigment1 [hp1]), Deetiolated1 (hp2), Zeaxanthin Epoxidase (hp3), and Intense pigment (Ip; gen

152 ZEAXANTHIN EPOXIDASE (ZEP) was the major contributor to

153 ified at different physical positions in the zeaxanthin epoxidase gene (ABSCISIC ACID DEFICIENT 1/ZEA

154 r flesh colour beta-carotene hydroxylase and zeaxanthin epoxidase were ranked first and forty-fourth

155 suggest that loss of function of DDB1, DET1, Zeaxanthin Epoxidase, and Ip up-regulates CHRC levels.

156 in epoxidase gene (ABSCISIC ACID DEFICIENT 1/ZEAXANTHIN EPOXIDASE, or ABA1/ZEP) in TG01 and TG10.

157 n, despite the near-complete violaxanthin to zeaxanthin exchange in LHC proteins.

158 tio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68

159 hich may be due to the strong requirement of zeaxanthin for rapid thermal dissipation and unsaturated

160 es not require a transthylakoid pH gradient, zeaxanthin formation, or the phosphorylation of light-ha

161 e, beta-cryptoxanthin, lycopene, lutein, and zeaxanthin from foods and supplements.

162 cell culture leads to the production of meso-zeaxanthin from lutein.

163 enhanced liberation and bioaccessibility of zeaxanthin from these tubular aggregates in goji berries

164 ression to cataract surgery in the no lutein/zeaxanthin group was 24%.

165 s (vde lhcsr KO and vde psbs KO) showed that zeaxanthin had a major influence on LHCSR-dependent NPQ,

166 oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on co

167 Daily supplementation with lutein/zeaxanthin had no statistically significant overall effe

168 y acids, and macular xanthophylls lutein and zeaxanthin have been associated with a lower risk of pre

169 antioxidants such as vitamin C, lutein, and zeaxanthin have been associated with lower incidence and

170 otenoids, particularly lycopene, lutein, and zeaxanthin, have been found to have important biological

171 he signal implies an increased efficiency of zeaxanthin in controlling chlorophyll triplet formation.

172 TCC, lutein and zeaxanthin in germ fractions were higher in non-corn cer

173 the differential distributions of lutein and zeaxanthin in human donor retinas mapped with confocal r

174 Distinguishing lutein from zeaxanthin in images of the human retina in vivo or in d

175 Lutein and zeaxanthin in macula from nonhuman primates were found t

176 ne, beta-cryptoxanthin, lutein, lycopene and zeaxanthin in minimally processed fresh food products, w

177 kale were stable (except alpha-carotene and zeaxanthin in peach) for 13, 9.7, 5.7, 2.5 and 7.5months

178 MP can be used as a biomarker of lutein and zeaxanthin in primate brain tissue.

179 in Arabidopsis thaliana The possible role of zeaxanthin in PSI photoprotection is discussed.

180 e prevalence of lutein, zeaxanthin, and meso-zeaxanthin in supplements is increasing.

181 2) assessed the value of substituting lutein/zeaxanthin in the AREDS formulation because of the demon

182 ut the physiology and function of lutein and zeaxanthin in the developing eye.

183 steps in the conversion of beta-carotene to zeaxanthin in the endosperm.

184 f the macular pigment carotenoids lutein and zeaxanthin in the human retina occurs early in life.

185 lex: (1) the accumulation of photoprotective zeaxanthin in the LHCI antenna and the PSI reaction cent

186 O2 knockout mice, unlike WT mice, accumulate zeaxanthin in their retinas.

187 nzyme responsible for the production of meso-zeaxanthin in vertebrates.

188 ole of the MXs (lutein, zeaxanthin, and meso-zeaxanthin) in AMD and report findings on AMD-associated

189 ne, beta-cryptoxanthin, lutein, lycopene and zeaxanthin) in participants.

190 The TRL AUC(0-10h) of lutein and zeaxanthin increased 4-5-fold (P < 0.001), and the TRL A

191 However, a combination of DeltapH and zeaxanthin increases the proportion of PsbS bound to the

192 ; P = 0.0106), but not with dietary lutein + zeaxanthin intake (r = 0.13; P = 0.50).

193 associations were found between lutein plus zeaxanthin intake and presence at baseline or developmen

194 Dietary lutein-zeaxanthin intake was associated with decreased likeliho

195 alpha-Carotene, beta-carotene, and lutein/zeaxanthin intakes were inversely associated with the ri

196 the CCD family, catalyzes the conversion of zeaxanthin into crocetin-dialdehyde in Crocus.

197 abolizes nonprovitamin A carotenoids such as zeaxanthin into long-chain apo-carotenoids.

198 meso-Zeaxanthin is an ocular-specific carotenoid for which th

199 Higher intake of bioavailable lutein/zeaxanthin is associated with a long-term reduced risk o

200 Zeaxanthin is highly concentrated in the fovea, extendin

201 We previously found that meso-zeaxanthin is produced in a developmentally regulated ma

202 nt violaxanthin is reversibly converted into zeaxanthin, is ubiquitous among green algae and plants a

203 Lutein and Zeaxanthin isomers (L/Zi) may counteract reactive oxygen

204 ons of alpha- and beta-carotene, lutein plus zeaxanthin (L + Z), and alpha-tocopherol were routinely

205 luate the efficacy and safety of lutein plus zeaxanthin (L+Z) and/or omega-3 long-chain polyunsaturat

206 9 eyes were analyzed (119 in the lutein plus zeaxanthin [L + Z] group and 120 in the placebo group).

207 ophylls, by characterizing the suppressor of zeaxanthin-less (szl) mutant of Arabidopsis (Arabidopsis

208 The aleurone layer had zeaxanthin levels 2- to 5-fold higher than lutein among

209 Mother serum zeaxanthin levels correlated with infant MPOD (r = 0.59,

210 Infant serum zeaxanthin levels correlated with MPOD (r = 0.68, P = 0.

211 ed a 60% lutein content reduction and 40% in zeaxanthin loss, showing lutein more susceptibility to i

212 lso by assessment of tocopherols, lutein and zeaxanthin losses.

213 Influence of kernel position on zeaxanthin, lutein, total carotenoid (TC) and quality pa

214 9 mug/g of carotenoids consisting of lutein, zeaxanthin, lycopene and beta-carotene.

215 (alpha-carotene, beta-carotene, lutein plus zeaxanthin, lycopene, and beta-cryptoxanthin) and risk o

216 e, beta-carotene, beta-cryptoxanthin, lutein/zeaxanthin, lycopene, folate, and alpha-tocopherol in re

217 Baseline concentrations of lutein/zeaxanthin, lycopene, sum of the 3 provitamin A caroteno

218 Dietary intakes of antioxidants (lutein/zeaxanthin [LZ], beta-carotene, and vitamin C), long-cha

219 vitamin C, folate, beta-carotene, lutein and zeaxanthin, magnesium, copper, and alcohol.

220 min A, vitamin B6, beta-carotene, lutein and zeaxanthin, magnesium, copper, docosahexaenoic acid, ome

221 R, 1.18; 95% CI, 0.96-1.45; P = 0.12; lutein/zeaxanthin main effect HR, 1.04; 95% CI, 0.85-1.28; P =

222 ogic studies suggest that dietary lutein and zeaxanthin may be of benefit in maintaining cognitive he

223 Our results imply that zeaxanthin may play a more important role than lutein in

224 Zeaxanthin nanoparticles (Zea-NP) and zeaxanthin nanoemulsion (Zea-NE) were incorporated in yo

225 Zeaxanthin nanoparticles (Zea-NP) and zeaxanthin nanoemu

226 n 1 eye were assigned randomly to lutein and zeaxanthin, omega-3 fatty acids, both, or placebo, and m

227 f dietary supplementation containing lutein, zeaxanthin, omega-3 polyunsaturated fatty acids, and vit

228 benefit of daily supplementation with lutein/zeaxanthin on AMD progression, secondary exploratory ana

229 AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery.

230 o mediate crocetin formation, did not cleave zeaxanthin or 3-OH-beta-apo-8'-carotenal in the test sys

231 for extracting xanthophylls such as lutein, zeaxanthin or beta-cryptoxanthin and carotenes such as b

232 ing could also be observed in the absence of zeaxanthin or STT7 kinase activity.

233 showed no significant sensitivity to low pH, zeaxanthin, or low detergent conditions.

234 ne (P = .052), folate (P = .056), and lutein/zeaxanthin (P = .077).

235 On the basis of delta(34)S, Y, U, Cu, Rb, zeaxanthin palmitate and total carotenoid content, discr

236 ared with a previously reported constitutive zeaxanthin pathway, our inducible pathway was shown to h

237 lementation with 10 mg of lutein and 2 mg of zeaxanthin per day can slow the rate of progression of a

238 These findings suggest that zeaxanthin played an important role in the adaptation of

239 Increased consumption of lutein-zeaxanthin predicted a lower risk of progression.

240 als are needed to determine whether maternal zeaxanthin prenatal supplementation can raise infant mac

241 is up-regulated 23-fold at the time of meso-zeaxanthin production during chicken eye development, an

242 (r = 0.36; P = 0.0142), with serum lutein + zeaxanthin (r = 0.44; P = 0.0049) and with skin caroteno

243 a lutein quencher in trimers, formation of a zeaxanthin radical cation in monomers.

244 a plain formulation showed a 35% lutein and zeaxanthin reduction.

245 Zeaxanthin retention in Y-NP and Y-NE was also determine

246 At the end of storage time, zeaxanthin retention was higher in Y-NP (22.31 +/- 2.53%

247 to-monomer transition, and in a violaxanthin/zeaxanthin-rich membrane, at an all-atom resolution.

248 extreme quintiles of predicted plasma lutein/zeaxanthin score, we found a risk reduction for advanced

249 ta-carotene, lutein, beta-cryptoxanthin, and zeaxanthin, showed no association with risk.

250 Our findings suggest that maternal zeaxanthin status may play a more important role than lu

251 r alternate strategies to improve lutein and zeaxanthin status.

252 ated the effectiveness of a high dose lutein/zeaxanthin supplement for MPOD volume and SC levels with

253 The effect of a high dose lutein/zeaxanthin supplement on macular pigment optical density

254 at is the long-term safety profile of lutein/zeaxanthin supplementation, should other carotenoids be

255 ticipants in the target tissue of lutein and zeaxanthin supplementation: The macula.

256 dase (VDE) is the key enzyme responsible for zeaxanthin synthesis from violaxanthin under excess ligh

257 ns, plants accumulate a specific carotenoid, zeaxanthin, that was shown to increase photoprotection.

258 lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin

259 y analysis of lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratio of the development of late

260 For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to catarac

261 of a binding protein for zeaxanthin and meso-zeaxanthin, the pi isoform of glutathione S-transferase

262 es of a bona fide CCD, and is able to cleave zeaxanthin, the presumed precursor of saffron apocaroten

263 -beta-ionone ring and that the conversion of zeaxanthin to crocetin dialdehyde proceeds via the C30 i

264 dy of research has linked macular lutein and zeaxanthin to reduced risk of degenerative eye disease.

265 show that the high light-induced binding of zeaxanthin to specific proteins plays a major role in en

266 cal evidence that native LHCSR protein binds zeaxanthin upon excess light stress.

267 can esterify lutein, beta-cryptoxanthin, and zeaxanthin using multiple acyl donors, yet it has a pref

268 or participants randomized to receive lutein/zeaxanthin vs -0.19 (99% CI, -0.25 to -0.13) for those r

269 at baseline, the direct comparison of lutein/zeaxanthin vs beta carotene showed hazard ratios of 0.76

270 tory analyses of direct comparison of lutein/zeaxanthin vs beta carotene showed hazard ratios of 0.82

271 eaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to ca

272 1.03 (95% CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin).

273 In exploratory analysis of lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratio of

274 For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios fo

275 beta-cryptoxanthin and beta-carotene, while zeaxanthin was absent in all sample.

276 utein nor on charge transfer events, whereas zeaxanthin was essential.

277 and beta-carotenes, lutein, violaxanthin and zeaxanthin was found under blue 33% treatment in compari

278 ly significant increase in plasma lutein and zeaxanthin was shown in the L + Z group after 3 months a

279 Zeaxanthin was shown to be stable, whereas alpha-caroten

280 Zeaxanthin was shown to be the most stable among all det

281 e degradation of this component, and that of zeaxanthin, was low, suggesting E- to Z-isomerization.

282 ncluding beta-carotene, lycopene, lutein and zeaxanthin were determined in three isolates of heterocy

283 y exploratory analyses suggested that lutein/zeaxanthin were helpful in reducing this risk.

284 Higher concentrations of 13-Z- and 9-Z-zeaxanthin were identified in puffed grains (2x and 37x

285 of alpha-carotene, beta-carotene, and lutein/zeaxanthin were inversely associated with risk of ER-, b

286 metric isomers of the carotenoids lutein and zeaxanthin were separated using TIMS (R > 110) for [M](+

287 Lutein and zeaxanthin were the predominant carotenoids; their level

288 Xanthophylls (lutein and zeaxanthin) were less sensitive to extrusion than carote

289 e, beta-cryptoxanthin, lycopene, lutein, and zeaxanthin) were measured by using reverse-phase HPLC, a

290 e studied the dependence of NPQ reactions on zeaxanthin, which is synthesized under light stress by v

291 n known to contain strikingly high levels of zeaxanthin, while the physical deposition form and bioac

292 Lutein and zeaxanthin within the brain might also increase temporal

293 macular pigment xanthophylls lutein (L) and zeaxanthin (Z) and n-3 fatty acids may reduce this damag

294 hin (V) conversion to antheraxanthin (A) and zeaxanthin (Z) ceased after 1 h.

295 An oral preparation containing lutein (L), zeaxanthin (Z), vitamin C, vitamin E, copper, and zinc o

296 f violaxanthin (V) to antheraxanthin (A) and zeaxanthin (Z).

297 n in response to supplemental lutein (L) and zeaxanthin (Z).

298 Here, to investigate chlorophyll (Chl)-zeaxanthin (Zea) excitation energy transfer (EET) and ch

299 complex of PSII (LHC-II) and the xanthophyll zeaxanthin (Zea) into proteoliposomes, we have tested th

300 tation with omega-3 fatty acids, lutein plus zeaxanthin, zinc, or beta-carotene had no statistically